Announcements Trials
Browse Landscape

Status

No longer available 4Approved for marketing 2

Sponsor Class

OTHER 4

Study Type

Expanded_access 4

Sponsor

Conditions

Lambert-Eaton Myasthenic Syndrome 4Myasthenic Syndromes, Congenital 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
No longer available × Expanded_access × Amifampridine × Clear all
NCT02012933 2019-12-11

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Oregon Health and Science University

No longer available

Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

NCT00704925 2019-10-30

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

University of California, Davis

No longer available

Lambert-Eaton Myasthenic Syndrome

NCT00994916 2019-07-09

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

University of Pittsburgh

No longer available

Lambert-Eaton Myasthenic Syndrome

NCT01378546 2013-07-18

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Columbia University

No longer available

Lambert-Eaton Myasthenic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡